
 Supplemental Table 1: Treatment Algorithms used to Identify Guideline-Concordant Initial Treatment as per the NCCN Guidelines for Metastatic Breast Cancer by Tumor Status

HER2- /HR-	a Chemotherapy	<ul style="list-style-type: none"> • Anthracyclines (Doxorubicin, Epirubicin, OR Pegylated liposomal doxorubicin) OR • Taxanes (Paclitaxel, Docetaxel, OR Albumin-bound paclitaxel) OR • Antimetabolites (Capecitabine OR Gemcitabine) OR • Other microtubule inhibitors (Vinorelbine OR Eribulin) OR • Other agents (Cyclophosphamide, Carboplatin, Mitoxantrone, Cisplatin, Etoposide, Vinblastine, Fluorouracil CI, OR Ixabepilone)
HER2- /HR+	a Aromatase inhibitors (Anastrozole OR Letrozole OR Exemestane) OR b Selective endocrine receptor modulators (Tamoxifen OR Toremifene) OR c Selective endocrine receptor down-regulator (Fulvestrant) OR d Chemotherapy	<ul style="list-style-type: none"> • Anthracyclines (Doxorubicin, Epirubicin, OR Pegylated liposomal doxorubicin) OR • Taxanes (Paclitaxel, Docetaxel, OR Albumin-bound paclitaxel) OR • Antimetabolites (Capecitabine OR Gemcitabine) OR • Other microtubule inhibitors (Vinorelbine OR Eribulin) OR • Other agents (Cyclophosphamide, Carboplatin, Mitoxantrone, Cisplatin, Etoposide, Vinblastine, Fluorouracil CI, OR Ixabepilone)
HER2+/ HR-	a (HER2 targeted therapy + Chemotherapy) OR	<ul style="list-style-type: none"> • Trastuzumab + Taxane (Docetaxel or Paclitaxel) OR • Pertuzumab + Trastuzumab + Taxane (Docetaxel or Paclitaxel) OR • Trastuzumab + Chemotherapy* OR • Other first-line therapies ((Trastuzumab + Paclitaxel ± Carboplatin) OR (Trastuzumab + Vinorelbine) OR (Trastuzumab + Capecitabine))
	b Trastuzumab only	

HER2+/ HR+	a	Aromatase inhibitors (Anastrozole OR Letrozole OR Exemestane) OR	
	b	Selective endocrine receptor modulators (Tamoxifen OR Toremifene) OR	
	c	Selective endocrine receptor down- regulator (Fulvestrant) OR	
	d	Other endocrine therapy (Megestrol acetate OR Fluoxymesterone OR Ethniyl estradiol) OR	
	e	Trastuzumab only OR	
	f	(HER2 targeted therapy + Chemotherapy)	<ul style="list-style-type: none">• Trastuzumab + Taxane (Docetaxel or Paclitaxel) OR• Pertuzumab + Trastuzumab + Taxane (Docetaxel or Paclitaxel) OR• Trastuzumab + Chemotherapy* OR• Other therapies ((Trastuzumab + Paclitaxel + Carboplatin) OR (Trastuzumab + Vinorelbine) OR (Trastuzumab + Capecitabine))

*Included chemotherapy claims for doxorubicin, gemcitabine, cyclophosphamide, fluorouracil
HER2: Human Epidermal Growth Factor Receptor 2; HR: Hormone Receptor